Anti-Human CTLA-4 Reference Antibody (GIGA-564, RUO) (HB651186)

Name: Anti-Human CTLA-4 Reference Antibody (GIGA-564, RUO)
Brand: abinScience
SKU: HB651186
Price: 370 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호	HB651186
종 반응성	Human
응용 분야	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
숙주 종	Human
클론성	Monoclonal
이소타입	IgG
클론 ID	GIGA-564
생물학적 활성	GIGA-564 (0.001-100 ug/mL) exhibits extremely low activity in blocking the binding of CTLA-4 to CD80 and CD86 in ELISA assays [1]. GIGA-564 (5 mg/kg; i.p.; once every 3 days; 3 doses) induces a lower level of peripheral Treg proliferation than Ipilimumab () in hCTLA-4 KI mice bearing MC38 tumors [1]. GIGA-564 (0.3 mg/kg; i.p.; once every 3 days; 3 doses) exhibits excellent anti-tumor activity in hCTLA-4 KI mice bearing MC38 tumors [1]. GIGA-564 (30 mg/kg; i.p.; once every 3 days; 9 doses) induces less toxicity than Ipilimumab () in hCTLA-4 knock-in (KI) and hCTLA-4/hPD-1 double knock-in (KI) mice, as evidenced by lower liver enzyme levels, reduced colitis, and the absence of skin lesions at the tested dose [1].
타겟	CD152, CTLA-4, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
내독소 수준	< 10 EU/mg
순도	>95% as determined by SDS-PAGE.
정제	Protein A/G purified from cell culture supernatant.
등록번호	P16410
형태	Liquid
저장 완충액	0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
대체 이름	GIGA-564, GIGA564, GIGA564
배경	Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy). 1. Schwartz, JC. et al. (2001) Nature 410, 604-8. PMID: 11279501 2. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502 3. Teft, WA. et al. (2006) Annual review of immunology 24, 65-97. PMID: 16551244 4. Linsley, PS. et al. (1991) The Journal of experimental medicine 174, 561-9. PMID: 1714933 5. Zheng, Y. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 1683-91. PMID: 18641304 6. Ramagopal, UA. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E4223-E4232. PMID: 28484017
참고 문헌	1. Stone E L, et al. GIGA-564, a third generation anti-CTLA-4 with minimal ability to block CTLA-4 binding to B7 ligands, has enhanced efficacy but reduced toxicity compared to ipilimumab in pre-clinical models//JOURNAL FOR IMMUNOTHERAPY OF CANCER. BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND: BMJ PUBLISHING GROUP, 2022, 10: A1443-A1443. [HB651186]
참고사항	For research use only. Not suitable for clinical or therapeutic use.